Evidence map›Paper›PMID 39846332›Full record

ArticleAdvanced healthcare materials2025

Salt-Compact Albumin as a New Pure Protein-based Biomaterials: From Design to In Vivo Studies.

Eya Aloui, Jordan Beurton, Claire Medemblik, Ludivine Hugoni, Igor Clarot, Ariane Boudier, Youri Arntz, Marcella De Giorgi, Jérôme Combet, Guillaume Fleith and 10 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Eya AlouiInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Jordan BeurtonInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Claire MedemblikInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Ludivine HugoniInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Igor ClarotUniversité de Lorraine, CITHEFOR, Nancy, F-54000, France.
Ariane BoudierUniversité de Lorraine, CITHEFOR, Nancy, F-54000, France.
Youri ArntzInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Marcella De GiorgiInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Jérôme CombetUniversité de Strasbourg, CNRS, Institut Charles Sadron UPR22, Strasbourg, F-67034, France.
Guillaume FleithUniversité de Strasbourg, CNRS, Institut Charles Sadron UPR22, Strasbourg, F-67034, France.
Eric MathieuInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Naji KharoufInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Leyla KocgozluInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Benoît HeinrichUniversité de Strasbourg, CNRS, Institut de Physique et Chimie des Matériaux de Strasbourg UMR 7504, Strasbourg, F-67034, France.
Damien FavierUniversité de Strasbourg, CNRS, Institut de Physique et Chimie des Matériaux de Strasbourg UMR 7504, Strasbourg, F-67034, France.
Michael BrenderUniversité de Strasbourg, CNRS, Institut Charles Sadron UPR22, Strasbourg, F-67034, France.
Fouzia BoulmedaisUniversité de Strasbourg, CNRS, Institut Charles Sadron UPR22, Strasbourg, F-67034, France.
Pierre SchaafInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Benoît FrischInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.
Philippe LavalleInserm UMR_S 1121, CNRS EMR 7003, Université Strasbourg, Biomaterials and Bioengineering, Centre de Recherche en Biomédecine de Strasbourg, Strasbourg, F-67000, France.ORCID 0000-0001-8798-912X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current biodegradable materials are facing many challenges when used for the design of implantable devices because of shortcomings such as toxicity of crosslinking agents and degradation derivatives, limited cell adhesion, and limited immunological compatibility. Here, a class of materials built entirely of stable protein is designed using a simple protocol based on salt-assisted compaction of albumin, breaking with current crosslinking strategies. Salt-assisted compaction is based on the assembly of albumin in the presence of high concentrations of specific salts such as sodium bromide. This process leads, surprisingly, to water-insoluble handable materials with high preservation of their native protein structures and Young's modulus close to that of cartilage (0.86 MPa). Furthermore, these materials are non-cytotoxic, non-inflammatory, and in vivo implantations (using models of mice and rabbits) demonstrate a very slow degradation rate of the material with excellent biocompatibility and absence of systemic inflammation and implant failure. Therefore, these materials constitute promising candidates for the design of biodegradable scaffolds and drug delivery systems as an alternative to conventional synthetic degradable polyester materials.

Indexed as

AlbuminsBiocompatible MaterialsAnimalsMaterials TestingMiceRabbitsAlbuminsBiocompatible Materialsalbuminbiodegradable materialsprotein‐based materialssalt‐assisted compaction

Identifiers

PMID39846332
PMCPMC11912121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.